Global Peripheral Arterial Disease (PAD) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

What is the Peripheral Arterial Disease (PAD) Market Size and Growth Rate?

• As per Data Bridge Market Research analysis, the peripheral arterial disease (PAD) market was valued at USD 873.01 million in 2025 and is projected to reach USD 1,739.52 million by 2033, growing at a CAGR of 9.00% from 2026 to 2033.
• Growth is primarily driven by the rising prevalence of PAD due to aging populations, increasing risk factors such as diabetes and hypertension, and continued advancements in minimally invasive treatment options.
• The rising incidence of cardiovascular diseases, growing awareness about PAD, advancements in diagnostic technologies, and the development of innovative treatment options such as drug-eluting stents and atherectomy devices are further strengthening market growth.
• The growing global focus on minimally invasive techniques such as endovascular surgery, which ensure faster recovery times and better patient outcomes, continues to reposition PAD treatment as a critical priority within cardiovascular care.

Market Size & Forecast

• Global Market Value (2025): USD 873.01 Million
• Expected Market Value (2033): USD 1,739.52 million
• Forecast CAGR (2026–2033): 9.00%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

What are the Major Takeaways of the Peripheral Arterial Disease (PAD) Market?

• North America dominated the global peripheral arterial disease (PAD) market with the largest revenue share of 38.76% in 2025, supported by advanced healthcare infrastructure, high awareness of cardiovascular diseases, and early adoption of cutting-edge medical technologies.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 11.30% from 2026 to 2033, fueled by rapid improvements in healthcare infrastructure, rising prevalence of diabetes and hypertension, and growing investments in vascular care across China, India, and Japan.
• The devices segment led the treatment type category with a 48.65% share in 2025, driven by the widespread use of peripheral vascular stents, angioplasty balloons, and atherectomy systems for minimally invasive interventional procedures.
• The catheters segment is the fastest-growing treatment type, projected to register a CAGR of 10.40%, reflecting rising adoption of PTA balloon catheters and guidewires in endovascular revascularization procedures.
• The hospitals segment dominated the end user category with a 54.32% revenue share in 2025, owing to the critical role of hospital-based cath labs in complex vascular interventions and post-procedural care.
• The hospital pharmacy segment accounted for 50.18% of the distribution channel market share in 2025, preferred for the regulated dispensing of prescription PAD medications and devices within clinical settings.

Report Scope and Peripheral Arterial Disease (PAD) Market Segmentation

What is the Key Trend in the Peripheral Arterial Disease (PAD) Market?

• Adoption of minimally invasive treatment technologies is a prominent and pivotal trend driving the global peripheral arterial disease market, as endovascular procedures, atherectomy, and drug-eluting stents increasingly replace traditional open surgical approaches.
• These advanced techniques provide patients with less invasive alternatives to traditional surgery, resulting in shorter recovery times, reduced complications, and improved overall outcomes.
• For instance, endovascular revascularization techniques such as angioplasty and stenting allow for targeted treatment of blocked arteries with smaller incisions, enabling faster recovery and less post-operative pain compared with conventional open surgery.
• In September 2026, Johnson & Johnson MedTech launched the Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter in Europe, a forward-facing IVL platform designed to modify calcium in extremely narrowed vessels, expanding treatment options for difficult-to-cross calcified PAD lesions.
• As device manufacturers and clinicians continue to prioritize precision and faster patient recovery, the adoption of minimally invasive and image-guided PAD treatment technologies is expected to accelerate, reinforcing this trend as a core driver of the global market.

What are the Key Drivers of the Peripheral Arterial Disease (PAD) Market?

• Increasing prevalence of risk factors and the aging population is significantly driving demand for PAD treatments, as diabetes, hypertension, smoking, and high cholesterol accelerate arterial plaque buildup and the narrowing of blood vessels.
• As people age, the likelihood of developing PAD increases, particularly among individuals with comorbid conditions such as diabetes, and PAD remains one of the most common causes of limb amputation, heightening demand for early diagnostic tools and effective treatment options.
• For instance, in 2021, the American Heart Association reported that more than 8.5 million people in the U.S. aged 40 and older suffer from PAD, with prevalence expected to rise further as the population ages.
• In 2020, the World Health Organization noted that by 2050, 16% of the global population will be over the age of 65, further underscoring the rising need for effective PAD management.
• As healthcare systems increasingly prioritize the management of chronic cardiovascular conditions, demand for advanced PAD diagnostic and treatment technologies continues to rise, ensuring better patient outcomes and reduced long-term healthcare costs.

Which Factors are Challenging the Growth of the Peripheral Arterial Disease (PAD) Market?

• High treatment and equipment costs present a significant challenge to market growth, particularly in low- and middle-income countries where advanced diagnostic devices and interventional procedures remain expensive.
• The cost of angiography systems, atherectomy tools, and procedures such as stenting and endovascular surgery can be prohibitively expensive for many healthcare providers, deterring hospitals and clinics in developing regions from adopting the latest PAD technologies.
• For instance, an August 2025 report published by the International Journal of Cardiology highlighted that the high cost of angioplasty and stenting procedures is a major barrier to PAD treatment in developing nations, limiting access to timely interventions.
• The financial burden of these treatments can also delay patient diagnosis and treatment, resulting in severe complications such as limb amputation, which continues to restrict the widespread adoption of innovative PAD management technologies across price-sensitive markets.

How is the Peripheral Arterial Disease (PAD) Market Segmented?

The peripheral arterial disease (PAD) market is segmented on the basis of treatment type, route of administration, end user, and distribution channel.

•  By Treatment Type

On the basis of treatment type, the global peripheral arterial disease market is segmented into devices, catheters, drugs, and others. The devices segment dominated the market with a 48.65% share in 2025, owing to the widespread use of peripheral vascular stents, atherectomy devices, embolic protection devices, and inferior vena cava filters across hospital-based interventional procedures.

The catheters segment is expected to witness the fastest growth at a CAGR of 10.40% from 2026 to 2033, driven by increasing adoption of PTA balloon catheters and guidewires that enable targeted, minimally invasive revascularization of blocked peripheral arteries.

•  By Route of Administration

On the basis of route of administration, the global peripheral arterial disease market is segmented into oral, parenteral, and others. The oral segment dominated the market with a 57.20% share in 2025 due to the widespread prescription of oral antiplatelet, lipid-lowering, and blood-pressure lowering medications for long-term PAD management.

The parenteral segment is expected to register the fastest CAGR of 9.80% from 2026 to 2033, driven by growing use of injectable anticoagulants and advanced biologic therapies in hospital and specialty clinic settings.

•  By End User

On the basis of end user, the global peripheral arterial disease market is segmented into hospitals, specialty clinics, and others. The hospitals segment dominated the market with a 54.32% share in 2025, owing to the availability of dedicated cath labs, multidisciplinary vascular teams, and advanced imaging infrastructure required for complex interventional procedures.

The specialty clinics segment is expected to witness the fastest CAGR of 10.10% from 2026 to 2033, driven by the increasing number of dedicated vascular and cardiovascular clinics offering outpatient PAD diagnosis and minimally invasive treatment.

•  By Distribution Channel

On the basis of distribution channel, the global peripheral arterial disease market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment dominated the market with a 50.18% share in 2025 due to its critical role in the regulated dispensing of prescription PAD medications alongside inpatient and post-procedural care.

The retail pharmacy segment is expected to witness the fastest CAGR of 9.60% from 2026 to 2033, supported by growing outpatient management of PAD and increasing patient preference for accessible, community-based medication dispensing.

Which Region Holds the Largest Share of the Peripheral Arterial Disease (PAD) Market?

• North America dominated the peripheral arterial disease market and accounted for the largest revenue share of 38.76% in 2025, supported by advanced healthcare infrastructure, high awareness of cardiovascular diseases, and a significant population affected by risk factors such as diabetes and hypertension.
• The region also benefits from high investment in research and development by leading medical device companies, favorable reimbursement policies, and early adoption of minimally invasive treatment methods such as angioplasty and stent placement, further strengthening North America's leadership position in the global market.

U.S. Peripheral Arterial Disease (PAD) Market Insight

The U.S. peripheral arterial disease market is experiencing steady growth, supported by a well-established healthcare system, rising PAD prevalence among the aging population, and a strong focus on cardiovascular health. Growing investments in advanced diagnostic tools and favorable reimbursement policies continue to improve accessibility to angioplasty, stenting, and atherectomy-based treatments, positioning the U.S. as the leading market within North America.

Germany Peripheral Arterial Disease (PAD) Market Insight

The Germany peripheral arterial disease market is expanding steadily, driven by a strong healthcare infrastructure, high prevalence of cardiovascular risk factors, and increasing adoption of minimally invasive endovascular procedures. Continuous investment in advanced vascular imaging and interventional technologies, along with supportive reimbursement frameworks, is further strengthening market growth across the country.

Asia-Pacific Peripheral Arterial Disease (PAD) Market Insight

The Asia-Pacific peripheral arterial disease market is expected to witness rapid growth, driven by rapid improvements in healthcare infrastructure, rising awareness about vascular diseases, and increasing prevalence of risk factors such as diabetes and hypertension. Countries such as China, India, and Japan are emerging as key markets due to their large populations, growing burden of cardiovascular disease, and expanding investment in advanced PAD diagnosis and treatment options.

India Peripheral Arterial Disease (PAD) Market Insight

India is expected to witness the highest CAGR in the global peripheral arterial disease market, driven by rising government and private sector investments in healthcare infrastructure and the ongoing expansion of PAD treatment options. Growing awareness of vascular health, increasing diabetes and hypertension prevalence, and improving access to interventional cardiology are further accelerating market growth across the country.

China Peripheral Arterial Disease (PAD) Market Insight

The China peripheral arterial disease market is growing rapidly, supported by rising government focus on cardiovascular health, expanding hospital infrastructure, and growing adoption of advanced interventional devices across public and private healthcare networks. Increasing awareness of PAD risk factors and rising investments in vascular research further position China as one of the fastest-growing markets in the region.

Which are the Top Companies in the Peripheral Arterial Disease (PAD) Market?

The peripheral arterial disease industry is primarily led by well-established companies, including:

• Bayer AG (Germany)
• Abbott (U.S.)
• Boston Scientific Corporation (U.S.)
• Biotronik (Germany)
• Cardinal Health (U.S.)
• Terumo Corporation (Japan)
• AngioDynamics (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Medtronic (Ireland)
• B. Braun SE (Germany)
• iVascular (Spain)
• Endologix LLC (U.S.)
• BD (U.S.)
• Meril Life Sciences Pvt. Ltd. (India)
• Lombard Medical (U.K.)
• Shockwave Medical Inc. (U.S.)
• Cordis (U.S.)
• Penumbra, Inc. (U.S.)
• BIOCARDIA, INC. (U.S.)
• Heraeus Group (Germany)

What are the Latest Developments in the Peripheral Arterial Disease (PAD) Market?

• In September 2026, Johnson & Johnson MedTech announced the European launch of its Shockwave Javelin Peripheral Intravascular Lithotripsy Catheter, a forward-facing IVL platform designed to modify calcium in extremely narrowed vessels, expanding treatment options for patients with difficult-to-cross calcified PAD lesions.
• In August 2026, Abbott received CE Mark approval in Europe for its Esprit BTK Everolimus Eluting Resorbable Scaffold System, a dissolving stent designed to treat blocked arteries below the knee in patients with the most severe form of PAD, before gradually dissolving after restoring blood flow.
• In May 2025, the American Heart Association published updated guidelines emphasizing early diagnosis, structured exercise therapy, and coordinated multispecialty care to reduce the risk of amputations in PAD patients, while also highlighting racial and ethnic disparities in PAD outcomes.
• In April 2025, Abbott received U.S. FDA approval for its Esprit BTK System, a resorbable scaffold system designed to keep below-the-knee arteries open and deliver a drug that supports vessel healing before completely dissolving over time.
• In March 2025, Becton, Dickinson and Company (BD) launched the AGILITY clinical study to evaluate the safety and effectiveness of its Vascular Covered Stent in treating PAD, conducted internationally across the U.S., Europe, Australia, and New Zealand with the goal of expanding treatment options for PAD patients.

SKU-54817